

Sherri R Davies

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5813602/publications.pdf>

Version: 2024-02-01

54
papers

15,795
citations

109321

35
h-index

144013

57
g-index

60
all docs

60
docs citations

60
times ranked

21864
citing authors

#	ARTICLE	IF	CITATIONS
1	Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. <i>Journal of Clinical Oncology</i> , 2009, 27, 1160-1167.	1.6	3,730
2	Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 736-750.	6.3	1,844
3	Proteogenomics connects somatic mutations to signalling in breast cancer. <i>Nature</i> , 2016, 534, 55-62.	27.8	1,384
4	Proteogenomic characterization of human colon and rectal cancer. <i>Nature</i> , 2014, 513, 382-387.	27.8	1,219
5	Genome remodelling in a basal-like breast cancer metastasis and xenograft. <i>Nature</i> , 2010, 464, 999-1005.	27.8	1,077
6	Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. <i>Cell</i> , 2016, 166, 755-765.	28.9	804
7	A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5222-5232.	7.0	676
8	Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. <i>Cell Reports</i> , 2013, 4, 1116-1130.	6.4	539
9	Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities. <i>Cell</i> , 2019, 177, 1035-1049.e19.	28.9	498
10	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2019, 179, 964-983.e31.	28.9	430
11	Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. <i>Nature Protocols</i> , 2018, 13, 1632-1661.	12.0	377
12	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <i>BMC Medical Genomics</i> , 2015, 8, 54.	1.5	352
13	Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1690-1704.	3.8	323
14	Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. <i>Arthritis and Rheumatism</i> , 1996, 39, 1896-1904.	6.7	235
15	PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2009, 69, 3955-3962.	0.9	198
16	Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. <i>Clinical Chemistry</i> , 2016, 62, 48-69.	3.2	187
17	CPTAC Assay Portal: a repository of targeted proteomic assays. <i>Nature Methods</i> , 2014, 11, 703-704.	19.0	150
18	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2402-2412.	7.0	132

#	ARTICLE	IF	CITATIONS
19	Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 379-390.	2.5	122
20	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , 2021, 53, 86-99.	21.4	118
21	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. <i>Nature Communications</i> , 2017, 8, 14864.	12.8	112
22	Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12909-12914.	7.1	105
23	An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1060-1071.	3.8	104
24	The prognostic effects of somatic mutations in ER-positive breast cancer. <i>Nature Communications</i> , 2018, 9, 3476.	12.8	89
25	Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. <i>Cell Reports</i> , 2020, 33, 108276.	6.4	83
26	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). <i>Npj Breast Cancer</i> , 2016, 2, .	5.2	80
27	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. <i>Cell Reports</i> , 2018, 24, 1434-1444.e7.	6.4	73
28	Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers. <i>Nature Communications</i> , 2016, 7, 12498.	12.8	69
29	Integrated Bottom-Up and Top-Down Proteomics of Patient-Derived Breast Tumor Xenografts. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 45-56.	3.8	68
30	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. <i>Nature Communications</i> , 2021, 12, 5086.	12.8	58
31	Site-1 protease is essential for endochondral bone formation in mice. <i>Journal of Cell Biology</i> , 2007, 179, 687-700.	5.2	55
32	Research-based PAM50 signature and long-term breast cancer survival. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 197-206.	2.5	53
33	Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. <i>Cancer Research</i> , 2018, 78, 2732-2746.	0.9	52
34	Reproducibility of Differential Proteomic Technologies in CPTAC Fractionated Xenografts. <i>Journal of Proteome Research</i> , 2016, 15, 691-706.	3.7	44
35	Alternative Splicing of Type II Procollagen Exon 2 Is Regulated by the Combination of a Weak 5' Splice Site and an Adjacent Intronic Stem-loop Cis Element. <i>Journal of Biological Chemistry</i> , 2005, 280, 32700-32711.	3.4	40
36	Distribution of the Transcription Factors Sox9, AP-2, and [Delta]EF1 in Adult Murine Articular and Meniscal Cartilage and Growth Plate. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 1059-1065.	2.5	35

#	ARTICLE	IF	CITATIONS
37	Using the CPTAC Assay Portal to Identify and Implement Highly Characterized Targeted Proteomics Assays. <i>Methods in Molecular Biology</i> , 2016, 1410, 223-236.	0.9	33
38	Computational identification and functional validation of regulatory motifs in cartilage-expressed genes. <i>Genome Research</i> , 2007, 17, 1438-1447.	5.5	30
39	Comprehensive Quantitative Analysis of Ovarian and Breast Cancer Tumor Peptidomes. <i>Journal of Proteome Research</i> , 2015, 14, 422-433.	3.7	26
40	Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. <i>Science Signaling</i> , 2017, 10, .	3.6	25
41	Doxycycline Inhibits Type X Collagen Synthesis in Avian Hypertrophic Chondrocyte Cultures. <i>Journal of Biological Chemistry</i> , 1996, 271, 25966-25970.	3.4	18
42	Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. <i>Journal of Proteome Research</i> , 2017, 16, 4523-4530.	3.7	17
43	In vivo human Cartilage Oligomeric Matrix Protein (COMP) promoter activity. <i>Matrix Biology</i> , 2005, 24, 539-549.	3.6	16
44	Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability*. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1630-1650.	3.8	14
45	miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1525-1533.	2.5	14
46	A promoter element of the CD-RAP gene is required for repression of gene expression in non-cartilage tissues in vitro and in vivo. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 857-868.	2.6	13
47	A novel tumor necrosis factor Î±-responsive CCAAT/enhancer binding protein site regulates expression of the cartilage-derived retinoic acid-sensitive protein gene in cartilage. <i>Arthritis and Rheumatism</i> , 2008, 58, 1366-1376.	6.7	12
48	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 147-161.	2.8	11
49	QuantFusion: Novel Unified Methodology for Enhanced Coverage and Precision in Quantifying Global Proteomic Changes in Whole Tissues. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 740-751.	3.8	8
50	Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. <i>Cancers</i> , 2020, 12, 3857.	3.7	8
51	Tissue-restricted expression of the Cdrap/Mia gene within a conserved multigenic housekeeping locus. <i>Genomics</i> , 2004, 83, 667-678.	2.9	7
52	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. <i>NAR Cancer</i> , 2022, 4, zcac014.	3.1	7
53	Estrogen Receptor Expression Is High but Is of Lower Intensity in Tubular Carcinoma Than in Well-Differentiated Invasive Ductal Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1507-1513.	2.5	3
54	Site-1 protease is essential for endochondral bone formation in mice. <i>Journal of Experimental Medicine</i> , 2007, 204, i28-i28.	8.5	0